An article co-authored by Ash Bullement and Anthony Hatswell has been published in the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) bimonthly new publication Value & Outcomes Spotlight. The article provides a summary of the key challenges faced when assessing curative interventions, alongside initiatives undertaken and illustrative case studies. You can read the article by following this Link
Ash Bullement will be attending the ISPOR International annual meeting in New Orleans on behalf of Delta Hat. Please get in touch if you’d like to arrange a meeting with Ash, and if attending please feel free to attend his talks on modelling in haemophilia, a review of NICE appraisals approach to capturing health-related quality of life, and the poster he is presenting on a simulation study of utility data.
Anthony Hatswell will be attending the NICE conference in Manchester on 9 July, if you’d like to arrange to meet for a coffee then please contact us.
Ash Bullement has recently had an article published in Value in Health regarding the survival extrapolation techniques for patients treated with cancer immunotherapy. The study considers a suite of candidate survival extrapolation methods that may be suitable, and concludes that those techniques that make use of external data appear to provide more accurate longer-term survival estimates. You can read the article by following this Link
An article authored by Ash Bullement and Anthony Hatswell has been published in Pharmacoeconomics Open regarding the cost-effectiveness of avelumab for the treatment of metastatic Merkel cell carcinoma. The analysis provides a summary of the cost-effectiveness model submitted as part of NICE’s technology appraisal of avelumab, including the use of spline-based survival models and time-to-death based utilities. You can find the open-access article by following this Link
An article authored by Ash Bullement has been published in the Journal of Medical Economics on the topic of survival extrapolation for patients treated with cancer immunotherapies. The article presents a review of extrapolation methods presented in company submissions to NICE, and assesses the accuracy of these extrapolations compared with later data. You can read the article for free by following this Link